Download Files:
IPN60090
$440 – $3,490
Products Details
Product Description
– IPN-60090 is an orally active and highly selective inhibitor of glutaminase 1 (GLS1; IC50=31 nM), with no activity observed against GLS-2. IPN-60090 exhibits excellent physicochemical and pharmacokinetic properties in vivo. IPN-60090 can be used for solid tumors research, such as lung and ovarian cancers[1][2].
Web ID
– HY-103671
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C24H27F3N8O3
References
– [1]Maria Emilia Di Francesco, et al. Gls1 inhibitors for treating disease. WO2016004404A2.|[2]Michael J Soth, et al. Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties. J Med Chem. 2020 Nov 12;63(21):12957-12977.
CAS Number
– 1853164-83-6
Molecular Weight
– 532.52
Compound Purity
– 99.47
SMILES
– O=C(NC1=NN=C(CC[C@@H](F)CN2N=NC(C(NC)=O)=C2)C=C1)CC3=NC(C)=CC(OC4CC(F)(F)C4)=C3
Clinical Information
– Phase 1
Research Area
– Cancer; Inflammation/Immunology
Solubility
– DMSO : 31.43 mg/mL (ultrasonic)
Target
– Glutaminase
Pathway
– Metabolic Enzyme/Protease
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
